Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5023 participants
OBSERVATIONAL
2022-05-01
2023-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Real-World Study on Extranodal Lymphoma
NCT06573099
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
NCT05907447
Real-World Study of DLBCL With Different Genetic Subtypes
NCT06026488
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
NCT02542111
Frontline of ASCT in High-risk DLBCL
NCT05831865
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No interventions need to be specified for this study
No interventions need to be specified for this study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Pathologically diagnosed with diffuse large B-cell lymphoma according to the 2016 WHO classification, including non-specific types and various special subtypes.
* 3\. Newly diagnosed DLBCL with involvement of extranodal organs.
* 4\. Patients who have received clinical treatment for lymphoma.
* 5.Patients with measurable lesions, including at least one effective efficacy assessment.
Exclusion Criteria
* 2\. Patients who cannot obtain effective efficacy assessment data.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhao Weili
First Deputy Director, Hematology Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENI-DLBCL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.